Fisetin: The Natural Senolytic Supplement

Among the most exciting developments in aging research is the discovery of senolytic compounds — agents that selectively eliminate senescent cells, the damaged cells that accumulate with age and contribute to tissue dysfunction and chronic inflammation. Among the most promising natural senolytics identified to date is fisetin, a flavonoid found in common fruits and vegetables.

Research published in prominent journals suggests that fisetin may possess potent senolytic activity alongside additional anti-inflammatory and antioxidant properties. This article examines what the science says about fisetin, its potential role in healthy aging, and what remains unknown.

What Is Fisetin?

Fisetin (3,7,3’,4’-tetrahydroxyflavone) is a naturally occurring flavonol — a subclass of flavonoids — found in various fruits and vegetables. Strawberries are the richest known dietary source, containing approximately 160 micrograms of fisetin per gram of fruit. Other sources include apples, persimmons, grapes, onions, cucumbers, and kiwi fruit.

Like other flavonoids, fisetin has been studied for various biological activities, including antioxidant, anti-inflammatory, and neuroprotective properties. However, it was its identification as a potent senolytic compound that catapulted fisetin into the spotlight of longevity research.

Understanding Cellular Senescence

To appreciate why fisetin has generated so much interest, it helps to understand the problem it may address: cellular senescence.

Senescent cells are cells that have permanently exited the cell cycle — they have stopped dividing but remain metabolically active. Senescence can be triggered by various stressors, including telomere shortening, DNA damage, oxidative stress, and oncogene activation. In youth, senescence serves important functions: it helps prevent damaged cells from becoming cancerous and plays roles in wound healing and embryonic development.

The problem emerges with age. As senescent cells accumulate in tissues over decades, they secrete a complex cocktail of inflammatory cytokines, chemokines, growth factors, and proteases collectively known as the senescence-associated secretory phenotype (SASP). The SASP creates a chronic inflammatory environment that may:

• Damage neighboring healthy cells
• Impair stem cell function and tissue regeneration
• Promote further senescence in nearby cells (paracrine senescence)
• Contribute to age-related tissue dysfunction
• Create a pro-inflammatory milieu linked to multiple age-related conditions

The accumulation of senescent cells has been linked in observational and animal studies to conditions including osteoarthritis, atherosclerosis, pulmonary fibrosis, neurodegeneration, and metabolic dysfunction. This has made the selective elimination of senescent cells — senolysis — an attractive therapeutic strategy.

The Landmark Fisetin Study

The study that established fisetin as a leading senolytic candidate was published in 2018 in EBioMedicine by Yousefzadeh, Zhu, and colleagues at the Mayo Clinic and the University of Minnesota. This research, led by the laboratories of Paul Robbins and Laura Niedernhofer, screened a panel of flavonoid polyphenols for senolytic activity and found that fisetin was the most potent.

Key findings from this landmark paper included:

• In vitro potency: Fisetin demonstrated the strongest senolytic activity among 10 flavonoids tested, selectively killing senescent human umbilical vein endothelial cells while sparing non-senescent cells.
• Reduced senescent cell burden in vivo: When administered to aged mice (equivalent to approximately 75 human years), fisetin reduced markers of cellular senescence in multiple tissues.
• Extended lifespan: Late-life treatment with fisetin extended the median and maximum lifespan of aged mice, even when treatment was started at the equivalent of very advanced age.
• Improved healthspan markers: Treated mice showed reduced age-related pathology and improved tissue function compared to untreated controls.

These results were particularly striking because fisetin is a naturally occurring compound with a well-established safety profile from dietary consumption, unlike some pharmaceutical senolytics that may carry significant side effects.

Earlier Research on Fisetin

The 2018 senolytic study built upon earlier research demonstrating fisetin’s biological activities relevant to aging.

A 2014 study by Currais and colleagues published in Aging Cell examined fisetin’s effects in the SAMP8 mouse model, which exhibits accelerated aging. The researchers found that fisetin administration reduced markers of oxidative stress and inflammation in the brain and improved cognitive function in aged animals. These neuroprotective effects appeared to be mediated through multiple pathways, including reduction of inflammatory markers and maintenance of glutathione levels.

A 2017 study published in Aging by Zhu and colleagues demonstrated that fisetin could selectively target senescent cells through inhibition of pro-survival pathways, particularly PI3K/AKT and the anti-apoptotic BCL-2 family proteins that senescent cells rely upon for survival.

Proposed Mechanisms of Action

Research suggests that fisetin may exert its senolytic and anti-aging effects through several interconnected mechanisms.

Senolytic Activity

Fisetin appears to selectively eliminate senescent cells by inhibiting the pro-survival pathways that these cells depend upon. Senescent cells upregulate anti-apoptotic proteins (including BCL-2, BCL-XL, and MCL-1) to resist the programmed cell death that would normally eliminate damaged cells. Fisetin may disrupt these survival signals, tipping senescent cells toward apoptosis while leaving healthy cells unaffected.

Anti-Inflammatory Effects

Beyond its direct senolytic activity, fisetin has been shown to inhibit NF-kB signaling, a master regulator of inflammatory gene expression. By reducing inflammation, fisetin may help mitigate the damaging effects of the SASP even before senescent cells are cleared.

Antioxidant Properties

As a flavonoid, fisetin possesses direct free-radical scavenging activity. It may also upregulate endogenous antioxidant defenses, including glutathione production and the Nrf2 pathway, which controls the expression of multiple antioxidant and detoxification enzymes.

Sirtuin Activation

Some research suggests that fisetin may activate SIRT1, a sirtuin deacetylase enzyme linked to longevity in multiple organisms. SIRT1 activation has been associated with improved mitochondrial function, enhanced DNA repair, and reduced inflammation.

Inhibition of mTOR Pathway

Fisetin has been shown to inhibit the mTOR signaling pathway in some experimental contexts. mTOR inhibition is one of the most well-validated interventions for lifespan extension in animal models, and compounds that modulate this pathway have attracted significant interest in longevity research.

Clinical Trials in Humans

The promising preclinical data has led to several clinical trials evaluating fisetin in human subjects.

The AFFIRM Trial

The Alleviation of Frailty, Inflammation, and Related Measures in Older Adults (AFFIRM) trial at the Mayo Clinic was designed to evaluate fisetin’s senolytic effects in older adults with frailty. This trial examined whether short courses of high-dose fisetin could reduce markers of senescent cell burden and inflammation.

The COVID-FISETIN Trial

During the pandemic, researchers initiated a trial evaluating whether fisetin’s senolytic and anti-inflammatory properties might benefit older adults hospitalized with COVID-19, given that cellular senescence and inflammation were implicated in severe disease outcomes.

Ongoing and Future Studies

Additional trials have examined fisetin in the context of osteoarthritis, chronic kidney disease, and other age-related conditions. These studies are at various stages of completion, and results are gradually becoming available, contributing to our understanding of fisetin’s effects and safety profile in human subjects.

Bioavailability Challenges

One of the significant challenges with fisetin supplementation is its relatively poor oral bioavailability. Like many flavonoids, fisetin undergoes extensive first-pass metabolism in the gut and liver, meaning that a relatively small percentage of an oral dose reaches systemic circulation in its active form.

Research has explored several strategies to improve fisetin bioavailability:

• Liposomal formulations that encapsulate fisetin in lipid vesicles
• Co-administration with piperine (from black pepper) or other bioavailability enhancers
• Nano-formulations that increase solubility and absorption
• Sunflower lecithin-based formulations that may improve absorption

The bioavailability question is important because the doses used in animal studies, when translated to human-equivalent doses, are typically much higher than what would be obtained from dietary sources alone. Most supplement formulations provide between 100-500 mg of fisetin per dose, while dietary intake is estimated at only 0.4 mg per day in the typical Western diet.

What We Still Do Not Know

Despite the promising research, several important questions about fisetin remain unanswered.

Optimal Dosing and Timing

The ideal dosing strategy for fisetin’s senolytic effects in humans has not been established. Animal studies have typically used intermittent high-dose protocols (reflecting the concept that senolytics need only be administered periodically, since senescent cells accumulate slowly). Whether this intermittent “hit-and-run” approach is optimal for humans, or whether continuous lower-dose supplementation might also provide benefits, remains unclear.

Long-Term Safety

While fisetin has a long history of dietary consumption and short-term studies have not revealed major safety concerns, the long-term effects of supplemental doses — which are many times higher than dietary intake — have not been thoroughly studied. Potential concerns include effects on drug metabolism, hormone levels, and interactions with medications.

Specificity of Senolytic Activity

While fisetin preferentially targets senescent cells in laboratory studies, the degree of selectivity in living human tissues is not fully characterized. Understanding whether fisetin might affect beneficial senescent cells (such as those involved in wound healing) or have off-target effects on non-senescent cells is important.

Interaction With Other Interventions

How fisetin interacts with other senolytic compounds, longevity-related supplements, or pharmaceutical medications is an area that requires further investigation.

Practical Considerations

For individuals interested in fisetin, several practical points are worth noting:

• Dietary sources first: Incorporating fisetin-rich foods like strawberries, apples, and onions into the diet provides fisetin along with many other beneficial compounds.
• Supplement quality varies: As with all supplements, the quality, purity, and actual fisetin content of commercial products may vary. Third-party testing certifications can provide some assurance of quality.
• Bioavailability matters: Formulations designed to enhance absorption may be more effective than standard fisetin powder.
• Not a substitute for medical care: Fisetin supplements are not approved to prevent, address, or manage any disease.

The Bigger Picture

Fisetin represents one of the most interesting convergences in longevity research: a naturally occurring compound with potent senolytic activity demonstrated in rigorous preclinical studies, now undergoing human clinical evaluation. If human trials confirm even a fraction of the benefits observed in animal models, fisetin could become an important tool in the longevity toolkit.

However, it is essential to maintain scientific rigor and temper enthusiasm with appropriate caution. The history of supplement research is littered with compounds that showed dramatic benefits in animal studies but produced modest or no effects in human trials. Until robust human data is available, fisetin remains a promising but unproven intervention for human aging.

As always, anyone considering fisetin supplementation should consult their healthcare provider, particularly if they are taking medications or have existing health conditions. The most exciting chapter of the fisetin story — the human clinical data — is still being written.